OBI.L Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 16:17):

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally...

Stats
Dagens volum	190 005
Gjennomsnittsvolum	308 867
Markedsverdi	10.78M
EPS	£-0.124 ( 2011-06-30 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.920
ATR14	£0.198 (3.58%)

Ondine Biomedical Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Ondine Biomedical Inc. Økonomi

Annual	2022
Omsetning:	£638 000
Bruttogevinst:	£287 000 (44.98 %)
EPS:	£-0.110

FY	2022
Omsetning:	£638 000
Bruttogevinst:	£287 000 (44.98 %)
EPS:	£-0.110

FY	2021
Omsetning:	£2.57M
Bruttogevinst:	£1.25M (48.81 %)
EPS:	£-0.257

FY	2020
Omsetning:	£1.79M
Bruttogevinst:	£649 000 (36.24 %)
EPS:	£-0.0833

Financial Reports:

No articles found.

Ondine Biomedical Inc.

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.